News
Exelixis' revenue growth through cabozantinib, mixed trial updates on zanzalintinib, and potential market shifts following ...
Zacks Investment Research on MSN20h
Xcel Energy Beats Q2 Earnings Estimates, Sales Miss, Adds CustomersXcel Energy Inc. XEL reported second-quarter 2025 operating earnings of 75 cents per share, which beat the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback